Replies to post #130327 on Biotech Values

[oc631]

DEB025 doesn’t need to show great efficacy as monotherapy. Its function in HCV cocktails will be to add modest incremental efficacy without generating any mutant HCV strains whatsoever (because it targets a host protein).

I understand its not intended to be a monotherapy but on the same note that's the drugs flaw. If its partnered outside the nuke class its more than likely that mutation will once again be an issue for the cocktail. The drug could find a market after years of nuke/riba or nuke monotherapy but I would expect this to be very limited.

[oc631]

NVS' PR doesn't appear to make the claim of having a bullet proof resistance profile.